Recent therapeutic advances in dermatology

JAMA

Volumn 283, Issue 2, 2000, Pages 175-177

  Lipper, Graeme M ^a   Amdt, Kenneth A ^c   Dover, Jeffrey S ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; TACROLIMUS;

DERMATITIS; DERMATOLOGY; DRUG EFFECT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; SHORT SURVEY; SKIN DISEASE; TOXIC EPIDERMAL NECROLYSIS; VERRUCA VULGARIS;

EID: 0343819745     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.2.175     Document Type: Short Survey

References (23)

1. Stanley MA. Mechanism of action of imiquimod Papillomavirus. Rev. 1999;10:23-29.
2. Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external congenital warts. Arch Dermatol. 1998;134:25-30.
3. Tyring ER, Arany I, Stanley MS, et al. A randomized, controlled molecular study of condylemata acuminate clearance during treatment with imiquimod. J Infect Dis. 1998;178:551-555.
4. Sofky YA, Borden EC, Wecks CE, et al. Inhibition of murine tumor growth by an interferon-inducing imidazoquimodinamine. Cancer Res. 1992;52:3528-3533.
5. Syed T, Goswani J, Ahmadpour O, et al. Treatment of molluscum contagiosum in males with an analog of imiquimod 1% in cream, a placebo-controlled, double-blind study. J Dermatol. 1998;25:309-313.
6. Wecks CE, Gibson SI. Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite IL-842 in human blood cells in vitro. J Interferon Res Cytokine. 1994;14:81-85.
7. Ruscha T, Assmann T, Romey B. Tacrolimus: the drug for the ban of the millennium? Arch Dermatol. 1999;135:574-580.
8. de Paulis A, Stellato C, Cirilio R, et al. Anti-inflammatory effect of FK-506 on human skin mast cells. J Invest Dermatol. 1992;99:723-727.
9. Reich K, Vente C, Neumann C. Topical tacrolimus for pyoderma gangrenosum. Br J Dermatol. 1998; 139:755-757.
10. Ruscka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med. 1997;337:816-821.
11. Zonneveld IM, Rubins A, Jablonska S, et al. Topical tacrolimus is not effective in discuss plaque pseriasis. Arch Dermatol. 1998;134:1101-1102.
12. Roujeau JC, Kelly J, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1996;333:1600-1607.
13. Rzany B, Correia O, Kelly JP, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis outing first weeks of antiepileptic therapy: a case control study. Lancet. 1999;353:2190-2194.
14. Robinson J, Cloffi W, McManus W, et al. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg. 1995;180:273-276.
15. McGee T, Munster A. Toxic epidermal necrolysis syndrome mortality rate reduced with early referral to regional ion center. Plast Reconstr Surg. 1988; 102:1018-1022.
16. Halebian P, Madden M, Finklestein J, et al. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg. 1986;204:503-512.
17. Egan C, Grant W, Morris S, et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol. 1999;40:458-461.
18. Caaldemenos G, Chrysomallis F, Sombolos K, et al. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol. 1997;36:218-221.
19. Heng MC, Allen SG. Efficacy of cyclophosphamide in max epidermal necrolysis. J Am Acad Dermatol. 1991;25:778-786.
20. Vlard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human infectious immunoglobulin. Science 1999;282: 423-433.
21. Wang B, Hering O, Mochenhangl M, et al. Histopathological and epidemiological characteristics of patients with erythema exudativism multiforms matter. Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 1996;133:6-33.
22. Wolkenstein P, Arfle H, Wechsler J, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol. 1996;132:710-714.
23. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 1998;352:1586-1589.